New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 31, 2012
08:08 EDTCOVCovidien raises FY13 Phamaceutical unit sales growth guidance to up 3%-6%
Covidien announced that as a result of the FDA approval of its generic version of CONCERTA and continued good operational performance, Covidien is increasing the fiscal 2013 net sales guidance for the Pharmaceuticals segment to 3%-6% above 2012 from the previous range of 1%-4% above 2012. There are no other changes to Covidienís previously announced 2013 guidance, the company said, adding that more details will be provided on January 25, 2013, when the company announces its first-quarter results. Covidien announced in December 2011 that it plans to spin off its Pharmaceuticals segment, Mallinckrodt, into a stand-alone company, a process expected to be completed in mid-2013.
News For COV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for COV

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use